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Objectives: To describe early-onset neonatal sepsis (EOS) epidemiology in a public maternity
hospital in Brasilia, Brazil.
Methods: We  deﬁned EOS as a positive blood culture result obtained from infants aged ≤72
hours of life plus treatment with antibiotic therapy for ≥5 days. Incidence was calculated
based on the number of cases and total live births (LB). This is a descriptive study comparing
the period of 2012–2013 with the period of 2014–September 2015, before and after implemen-
tation  of antibiotic prophylaxis during labor for group B streptococcus (GBS) prevention,
respectively.
Results: Overall, 36 infants developed EOS among 21,219 LB (1.7 cases per 1000 LB) and 16 died
(case fatality rate of 44%). From 2014, 305 vaginal-rectal swabs were collected from high-risk
women and 74 (24%) turned out positive for GBS. After implementation of GBS prevention
guidelines, no new cases of GBS were detected, and the EOS incidence was reduced from 1.9
(95% CI 1.3–2.8) to 1.3 (95% CI 0.7–2.3) cases per 1000 LB from 2012–2013 to 2014–September
2015 (p = 0.32).
Conclusions: Although the reduction of EOS incidence was not signiﬁcant, GBS colonization
among pregnant women was high, no cases of neonatal GBS have occurred after implemen-tation of prevention guidelines.
©  2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an
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coccus agalactiae,  also referred as group B streptococcus (GBS),open access article 
IntroductionEarly-onset sepsis (EOS) in neonates is a feared and severe
complication with high fatality rates. In developed countries,
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the epidemiology of EOS has been well described with Strepto-and Escherichia coli responsible for most of the severe cases.1,2
Additionally, prevention strategies based on GBS screening
and intrapartum antibiotic prophylaxis (IAP) to reduce vertical
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ransmission of invasive GBS infection have been imple-
ented for more  than a decade.3,4 As a consequence, the
ncidence of GBS infection in the United States was reduced
rom 1.7 cases per 1000 live births in the early 1990s to 0.34
ases per 1000 live births after the implementation of antibi-
tic prophylaxis during labor.3
Nevertheless, the epidemiology of EOS has rarely been
escribed in developing countries, including Brazil. One Brazil-
an study, published more  than a decade ago, described GBS
s the pathogen responsible for 50% of culture-proven EOS.5
he incidence of GBS infections in Brazil has ranged from 0.39
nd 1.0 per 1000 live births.6–9 The use of IAP has not been
dopted as a national strategy to prevent GBS disease, and no
ata concerning the impact of IAP have been published in the
ountry.
Therefore, we  present EOS data from our hospital, which
s the largest public maternity hospital in Brasilia, Brazil. We
ave implemented GBS screening and risk-based IAP in 2014,
nd herein we  compare the epidemiology of EOS in the periods
efore and after the implementation of IAP.
ethods
ettings  and  GBS  prophylaxis  protocol
ur hospital is the largest public maternity hospital in Brasilia,
entral Brazil. It is a regional referral center for preterm-births
nd neonatal surgery; it has a 30-bed neonatal intensive care
nit (NICU) and an intermediate care unit with 16 beds. Before
014, there was no policy for GBS screening and prophylaxis.
AP was implemented in January 2014, based on the latest
enters for Disease Control and Prevention (CDC) guidelines,3
nd consisted of a protocol that instructed the collection of
 vaginal-rectal swab for GBS screening for every woman ≥24
eeks of pregnancy admitted to the hospital with premature
abor or premature rupture of membranes. Additionally, it rec-
mmended IAP for (1) every woman with a positive GBS swab;
2) every woman, regardless of swab result, with a positive
rine culture for GBS any time during pregnancy, or with a his-
ory of a previous child with GBS sepsis; and (3) every woman
ith an unknown GBS colonization status, who was in labor
37 weeks of pregnancy or ≥18 h of rupture of membranes or
ith fever (temperature ≥38 ◦C) during labor (Fig. 1). It is impor-
ant to note that GBS screening during prenatal care was not a
olicy and that the vast majority of women had an unknown
BS status colonization upon arrival at the maternity hospital.
The swab was collected and immediately placed by the
ssistant physician in the Todd-Hewitt broth, a selective
nrichment broth used to identify GBS, and then forwarded to
he microbiology laboratory. After enrichment, GBS was iso-
ated by subcultures on blood agar plates with CAMP-disk test
or presumptive identiﬁcation.
Infant blood cultures were submitted to an automated




ystem). Then, an automated panel of bacterial identiﬁca-
ion (MicroScan Walk-Away
®
Dade Behring Inc.) was used to
dentify bacteria species and perform antimicrobial suscep-
ibility test. The laboratory used the Clinical and Laboratory 1 7;2  1(1):92–97 93
Standards Institute (CLSI) manual for interpretation of mini-
mum inhibitory concentrations (MIC).10
Data  collection  and  statistical  analysis
We  obtained the positive blood culture data from the micro-
biology laboratory database for the period of January 2012 to
September 2015. Similarly, the number of vaginal-rectal swabs
collected in the maternity hospital and their positivity rate
after the implementation of the protocol, from January 2014
to September 2015 were also abstracted.
EOS was deﬁned as isolation of a pathogen from blood
culture samples drawn within 72 h of birth plus antibiotic
treatment for ≥5 days or death <5 days while on antibiotic
treatment. Coagulase-negative staphylococci (CoNS) grown
alone in a single culture bottle were considered contaminants.
Patients’ records were reviewed, and maternal and
infant information was collected. The maternal information
included gestational age, time of rupture of membranes, pres-
ence of intrapartum fever, diagnosis of chorioamnionitis, type
of delivery, status of GBS colonization, IAP treatment, and
antibiotics received. The infants’ information included date of
birth, date of NICU admission, sex, birth weight, and outcome
(death or discharge from hospital). Antibiotic susceptibility
data were analyzed, if available.
The incidence of EOS was calculated using the number
of EOS divided by the numbers of live births (LB) during the
period of study. We  analyzed the data descriptively, using pro-
portions for discrete variables and the median for continuous
variables. The data were examined overall and between two
periods: before (2012 and 2013) and after (2014 and 2015) the
implementation of the GBS prevention protocol. We  used Chi-
square test and a 95% conﬁdence interval (95% CI) to compare
the EOS incidence rates between these two  periods. We also
compared data between infants infected with GBS and E. coli.
Results
Pathogens  and  infection  rates
During 2012–2013, there were 26 cases of EOS and 13,627 LB,
an incidence of 1.9 per 1000 LB (95% CI 1.3–2.8); 12 infants
died, a fatality rate of 46%. During 2014–September 2015, there
were 10 cases of EOS and 7592 LB, an incidence of 1.3 per
1000 LB (95% CI 0.7–2.3); 4 infants died, a fatality rate of 40%.
Thus, for the whole period of study there were 36 cases of EOS
and 21,219 LB, an incidence of EOS of 1.7 per 1000 LB (95%
CI 1.2–2.3), and a total of 16 deaths, an overall fatality rate of
44%. There was no signiﬁcant difference in the incidence of
EOS between the two periods (p = 0.32).
The distribution of pathogens isolated during the study
period is presented in Table 1. GBS was the main pathogen
isolated from 36 infants, but remarkably no new cases of
GBS have been isolated since the implementation of IAP.
E. coli was the second most frequently isolated pathogen, fol-
lowed by Staphylococcus aureus,  other Streptococcus species, and
Enterococcus faecalis among Gram positive bacteria and other
enteric bacilli and Haemophilus inﬂuenza among Gram nega-
tive bacteria. There was only one infant with more  than one
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Obtain vaginal-rectal swab for GBS screening for every wo men  ≥24 weeks of 
pregnancy, upon  arrival  at  the  maternity  hospital with preterm labor or with pre mature 
rupture of membranes 
Intrapartum GBS prophylaxis indicated
- Previous infant with  invasive GBS disease 
- GBS bacteriuria d uri ng any trime ster of the current pregnancy 
- Positive GBS vaginal-rectal screening culture in late gestation during current
  pregnancy 
- Unknown GBS status at the onset of labor (culture not done, incomplete, or results
  unknown) and any of the following: 
         - Delivery at < 37 weeks’ gestation 
         - Amniotic membrane rupture ≥18 hours 
         - Intrapartum temperature ≥38.0°C 
Intrapartum antibiotic prophylaxis during labor 
- Penicillin G,  5 million units IV i nitial dose, the n 2,5 - 3 million units IV every 4
  hours until delivery 
OR 
- Ampicilli n, 2 g IV initial dose, then 1 g IV every 4 hours until  deli very  
If patient has a history of allergy  (anaphylaxis,  angioede ma, respiratory distress or 
urticaria) after  receiving  penicillin  or  a cephalosporin 
- Clinda mycin 900mg IV every 8 hours until delivery 
Intrapartum GBS prophylaxis not indicated
- Negative vaginal-rectal GBS screening culture during the current pregnancy,
  regardless of intrapartum risk factors 
- Cesarean delivery per for med befo re onset of labor on a wo man with  intact  amnioti c 
  membranes, regardless of GBS colonization status or gestational age 
Observations 
- A negative GBS screen is considered valid for 5 weeks, after this ti me, repeat 
  scree ning  if the wo men  has  not  delivered 
- If the women  is recei ving  ampicillin  and /or  cli ndamycin  for pr esu med
  chorioa mnioniti s or prematur e rupture of membranes during labor, she d oes not need 
  additional antibi otic   
Fig. 1 – Group B streptococcal colonization screening and use of intrapartum antibiotic prophylaxis protocol for women with
preterm labor or premature rupture of membranes, Brasilia, Brazil.
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Table 1 – Distribution of pathogens isolated from
early-onset neonatal sepsis during 2012–2013 and
2014–September 2015, Brasilia, Brazil.




7  0 7
Staphylococcus aureus 3 1 4
Streptococcus mitis/oralis 3 0 3
Streptococcus salivarus 2  0 2
Enterococcus faecalis 2  0 2
Streptococcus anginosus 1  1 2
Streptococcus pneumoniae 0 1 1
Streptococcus bovis 0 1 1
Streptococcus dysgalactiae 0 1 1
Staphylococcus capitis 0  1 1
Gram negative
Escherichia coli 4 1 5
Klebsiella pneumoniae 1 1 2
Haemophilus inﬂuenzae 0 2 2
Acinetobacter lwofﬁi 1 0 1
Enterobacter cloacae 1 0 1
Enterobacter
cloacae + Elizabethkingia





























Total 26 10 36
icroorganism grown in culture. There were 12 blood cultures
ith CoNS, but only one included as the remaining were con-
idered contaminants.
All seven GBS isolates were sensitive to penicillin, ampi-
illin, and vancomycin; they were not tested for clindamycin
usceptibility. All ﬁve E. coli isolates were resistant to ampi-
illin and sensitive to third generation cephalosporins; one
solate was gentamicin resistant. No S. aureus was methicillin
esistant and no E. faecalis was vancomycin resistant.
aternal  and  neonatal  clinical  features
ll 36 infants developed symptomatic illness (required blood
ressure support or had respiratory distress) of EOS during
he period of study; all received ampicillin, penicillin, or cefa-
olin with gentamicin. Eighteen (50%) were male and 19 (53%)
ere born through vaginal delivery. Twenty-nine (81%) were
reterm (<37 weeks of gestation); the median gestational age
as 31 weeks (24–41 weeks). Twenty-one (58%) were ≤1500 g;
he median birth weight was 1307.5 g (470–3800 g).
Eighteen (50%) pregnant women had rupture of mem-
ranes at delivery. For the other 18 pregnant women, with
upture of membranes before delivery, the median duration of
embrane rupture was 72 h (1 h to 42 days). Overall, 14 (39%)
ad a period of rupture of membranes longer than 18 h. Seven
19%) pregnant women had fever or a diagnosis of presumed
horioamnionitis during labor.
mplementation  of  GBS  prophylaxisuring 2012–2013, among the 26 pregnant women who had
n infant with EOS, none of the women had a vaginal-rectal
wab result at labor. According to the latest guidelines,3,4
hen considering the unknown status of GBS colonization, 1 7;2  1(1):92–97 95
21 (81%) women met  the criteria for receiving IAP (12 had
premature labor; six had premature labor and rupture of
membranes ≥18 h; two had premature labor, rupture of mem-
branes ≥18 h and fever during labor; and one had term labor
and rupture of membrane ≥18 h). However, only three (11%)
women received antibiotics during labor: two  women received
clindamycin because of presumed chorioamnionitis, and one
received ampicillin and azithromycin for prolonged prema-
ture rupture of membranes.
From 2014, the IAP protocol was implemented, and until
September 2015, 305 vaginal-rectal swabs were collected from
women admitted with preterm labor and 74 (24%) were posi-
tive. Out of 10 pregnant women who had an infant with EOS,
only one had a vaginal-rectal swab collected that turned out
negative. However, the result was known after delivery. Only
one woman had a term labor with unknown GBS coloniza-
tion status, no risk factors for EOS and thus, did not have
indications for IAP. Therefore, nine (90%) women should have
received IAP, according to the protocol (three had premature
labor; one had premature labor and rupture of membranes
≥18 h; four had premature labor, rupture of membranes ≥18 h
and fever during labor; and one had premature labor and
fever during labor); however, only ﬁve (55.5%) received antibi-
otics during labor: four received clindamycin for presumed
chorioamnionitis, and one received ampicillin as prophylaxis,
according to protocol, because she had a preterm labor and
rupture of membranes ≥18 h.
Group  B  Streptococcus  and  E.  coli
The total number of infants with GBS infection was seven with
an incidence rate of infection during 2012–2013 was 0.51 per
1000 LB or 0.33 per 1000 LB for the whole period of study. No
case of EOS due to GBS was detected after the implementa-
tion of the IAP protocol. Four (57%) infants were preterm; the
median birth weight among GBS infected infants was 2751 g
(569–3800 g). Three infants died, a fatality rate of 43%.
The total number of infants with E. coli infection was ﬁve
with an incidence rate of infection with E. coli was 0.23 per 1000
LB during the whole period of study. All infants were preterm;
the median birth weight among infants infected with E. coli
was 1270 g (855–2020 g). Four infants died, a fatality rate of 80%.
Discussion
This analysis of a regional referral maternity hospital in Brazil
with approximately 20,000 LB shows that the burden of EOS is
concentrated among preterm infants. The incidence density
of culture proven EOS was 1.7 cases per 1000 LB and the fatality
rate was 44%, ﬁgures that are higher than those observed in
developed countries. EOS incidence density was 0.98 per 1000
LB in the United States2 and 0.9 per 1000 LB in England.11
GBS and E. coli have been the predominant causative
microorganisms of EOS, but in this study it corresponded to
only a third of cases and almost one half of deaths. Other
microorganisms, especially Gram positive bacteria, such as S.
aureus, other Streptococcus species, and E. faecalis corresponded
to a signiﬁcant share of cases of EOS in our study. Although
Staphylococcus and other Streptococcus species are viewed as
 i s . 2
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possible contaminants, all the infants who had blood cultures
with these pathogens, presented clinical or laboratory ﬁnd-
ings suggestive of infection and received antibiotics. As the
importance of CoNS as an EOS pathogen remains controver-
sial, we  only considered CoNS as the cause of EOS in the case of
one infant who  had more  than one culture growing CoNS. It is
worthy to note that there was no case of Listeria monocytogenes.
The strategy of IAP in developed countries has reduced the
incidence of EOS by reducing the cases of GBS. The incidence of
GBS in our study (0.51 per 1000 LB), before the implementation
of IAP, is within the range of previous Brazilian studies,6–9 but
higher than the incidence observed in developed countries,
more  than a decade after IAP implementation.3,4 We  found
a positive vaginal-rectal swab prevalence of 24%. This is
similar to the range observed in other Brazilian studies of
17.9–27.6%12–14 and the prevalence of 26% observed in the
United States.15 Despite this high rate of women with colo-
nization, screening of GBS during prenatal care and IAP during
labor is not a national policy in Brazil. During the period of
study, more  than 80% of women who had an infant with EOS
should have received IAP, according to the latest American
and European guidelines,3,4 but only 11% of women during
2012–2013 and 55.5% of women during 2014–September 2015,
respectively, received IAP. These were missed opportunities
for GBS prophylaxis in general, and for preterm labor in par-
ticular; antibiotics were more  likely to have been prescribed
when there was a presumed diagnosis of chorioamnionitis
or a long period of membrane rupture. A Brazilian study had
already revealed a 57% inappropriate compliance with the IAP
protocol.16 Nevertheless, we observed 18 months following the
implementation of the IAP protocol, no new cases of GBS have
appeared, and the crude EOS incidence has been reduced.
The rational choice of antibiotics for the infant with pre-
sumed infection requires review of antibiotic susceptibility
of the predominant organisms that cause the disease at a
local level. Ampicillin and gentamicin are the recommended
empiric antibiotics for the infant at risk of EOS. In our study, all
the GBS were sensitive to ampicillin or penicillin, but one out
of ﬁve E. coli infections was resistant to gentamicin. This ﬁnd-
ing is worrisome because previous studies have already shown
that E. coli has become the most frequent pathogen among
preterm infants, who  are at the highest risk of severe disease
and death.17–19 The incidence of E. coli (0.23 per 1000 LB) in
our study is very close to that observed in the United States
(0.28 per 1000 LB).2 The median birth weight of infants infected
with E. coli was lower than that observed in infants infected
with GBS, with a higher fatality rate. Data from developing
countries have already reported 13% gentamicin resistance
among E. coli neonatal infections.20
Among limitations of the present study, it did not have an
uninfected comparison group to assess risk factors and GBS
prevention strategies more  broadly. Additionally, we have a
relative small sample size for an unusual outcome, culture-
proven EOS, and a short period of time after implementation
of IAP strategy. These factors may explain why we  did not ﬁnd
a signiﬁcant difference between the EOS incidences for the two
periods of study. Moreover, our results are ecological ﬁndings,
and it is not possible to afﬁrm that the reduction in GBS infec-
tions was caused only by the IAP protocol. We  also had limited
external validity because this study was carried out in only 0 1 7;2  1(1):92–97
one single regional maternity hospital. Different situations
may exist in Brazil because it is such a diverse country. Larger
studies, including multiple centers, longer time periods, and
a different design controlling for confounding variables are
necessary to better describe the epidemiology of EOS and to
evaluate the impact of IAP strategy in Brazil.
In conclusion, EOS incidence in the studied scenario seems
higher than that observed in developed countries. EOS is con-
centrated among preterm infants and GBS and E. coli are
the main pathogens of neonatal infection. Although we did
not ﬁnd a signiﬁcant difference in EOS incidence before and
after the implementation of IAP in our hospital, the EOS inci-
dence was reduced and no new cases of GBS were observed.
Evidence-based strategies to reduce the burden of EOS should
be implemented, along with efforts to decrease preterm birth
rates and to reduce the number of deaths associated with
these infections.
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